Display options
Cite
Monsalve P. Decoding PERG: A neuro-ophthalmic retinal ganglion cell function review. Curr Ophthalmol Rep. 2019;7(1):51-58doi: 10.1007/s40135-019-00199-9.
Monsalve, P. (2019). Decoding PERG: A neuro-ophthalmic retinal ganglion cell function review. Current ophthalmology reports, 7(1), 51-58. https://doi.org/10.1007/s40135-019-00199-9
Monsalve, Pedro. "Decoding PERG: A neuro-ophthalmic retinal ganglion cell function review." Current ophthalmology reports vol. 7,1 (2019): 51-58. doi: https://doi.org/10.1007/s40135-019-00199-9
Monsalve P. Decoding PERG: A neuro-ophthalmic retinal ganglion cell function review. Curr Ophthalmol Rep. 2019 Mar;7(1):51-58. doi: 10.1007/s40135-019-00199-9. Epub 2019 Feb 13. PMID: 31737438; PMCID: PMC6857793.
Copy Download .nbib Format: NLM
Share it on

Curr Ophthalmol Rep. 2019 Mar;7(1):51-58. doi: 10.1007/s40135-019-00199-9. Epub 2019 Feb 13.

Decoding PERG: A neuro-ophthalmic retinal ganglion cell function review.

Current ophthalmology reports

Pedro Monsalve

Affiliations

  1. Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, 900 NW 17 Street, Miami, FL, 33136.

PMID: 31737438 PMCID: PMC6857793 DOI: 10.1007/s40135-019-00199-9

Abstract

PURPOSE OF REVIEW: Currently, the clinical evaluation of neuro-ophthalmologic diseases are mainly focused on identifying stages where structural or functional damage occur. Recognition of retinal ganglion cell (RGC) functional patterns as well as monitoring RGC dysfunction can be performed using steady-state pattern electroretinogram (PERG). The analysis of the amplitude and latency shift aid on providing information on early damage or monitoring of the RGC, allowing for prompt clinical intervention and management modification, potentially changing the natural history of the disease. The purpose of this article is to review the latest findings in PERG, in early manifest glaucoma, non arteritic ischemic optic neuropathy, multiple sclerosis with unilateral recovered optic neuritis and its fellow eyes.

RECENT FINDINGS: The steady-state PERG responses provide new and early specific information in neuro-ophthalmic diseases affecting the inner retina.

SUMMARY: Steady state PERG presents specific amplitude and latency outcomes based on the neuro-ophthalmic disease affecting the inner retina, allowing early recognition of changes at the level of RGC and the degree of RGC dysfunction. In addition, PERG alterations may be induced in healthy subjects as well as susceptible eyes using different stress tests such as head down tilting or water drinking tests.

Keywords: Glaucoma; Multiple sclerosis; Non-arteritic ischemic optic neuropathy (NAION); Optic Neuritis; Retinal ganglion cell function; Steady state PERG

Conflict of interest statement

Conflict of Interest Pedro Monsalve declare that he has no conflict of interest.

References

  1. Nat Rev Neurol. 2014 Aug;10(8):447-58 - PubMed
  2. Ophthalmic Physiol Opt. 1997 Mar;17(2):128-32 - PubMed
  3. J Neuroophthalmol. 2012 Dec;32(4):354-8 - PubMed
  4. Neuropsychiatr Dis Treat. 2018 Sep 05;14:2281-2285 - PubMed
  5. Invest Ophthalmol Vis Sci. 2013 Mar 28;54(3):2346-52 - PubMed
  6. J Clin Neurosci. 2006 Jan;13(1):55-9 - PubMed
  7. Eur J Neurol. 2008 Aug;15(8):839-45 - PubMed
  8. Prog Retin Eye Res. 2001 Jul;20(4):531-61 - PubMed
  9. Vision Res. 2009 Mar;49(5):505-13 - PubMed
  10. Optom Vis Sci. 2008 Jun;85(6):386-95 - PubMed
  11. J Glaucoma. 2008 Sep;17(6):436-41 - PubMed
  12. Exp Eye Res. 2015 Dec;141:164-70 - PubMed
  13. Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1296-302 - PubMed
  14. Clin Neurophysiol. 2018 Sep;129(9):1813-1818 - PubMed
  15. Eur J Ophthalmol. 2001 Jul-Sep;11 Suppl 2:S41-9 - PubMed
  16. Curr Opin Neurol. 2008 Feb;21(1):16-21 - PubMed
  17. Electroencephalogr Clin Neurophysiol. 1994 Nov;92(6):480-6 - PubMed
  18. J Clin Neurophysiol. 2013 Aug;30(4):376-81 - PubMed
  19. Doc Ophthalmol. 2017 Jun;134(3):185-193 - PubMed
  20. Front Neurol. 2017 Dec 22;8:710 - PubMed
  21. Invest Ophthalmol Vis Sci. 2011 Jun 16;52(7):4300-6 - PubMed
  22. Vision Res. 1992 Jul;32(7):1199-209 - PubMed
  23. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2520-7 - PubMed
  24. J Glaucoma. 2018 May;27(5):429-432 - PubMed
  25. Doc Ophthalmol. 2014 Feb;128(1):53-8 - PubMed
  26. Br J Ophthalmol. 2006 Mar;90(3):262-7 - PubMed
  27. Clin Neurophysiol. 2013 Aug;124(8):1652-8 - PubMed
  28. Brain. 2001 Sep;124(Pt 9):1813-20 - PubMed
  29. J Glaucoma. 2017 May;26(5):459-465 - PubMed
  30. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2411-8 - PubMed
  31. Arch Ophthalmol. 2000 Mar;118(3):378-84 - PubMed
  32. Optom Vis Sci. 1992 Feb;69(2):122-8 - PubMed
  33. Cesk Slov Oftalmol. 2002 Jul;58(4):259-64 - PubMed
  34. Doc Ophthalmol. 2018 Jun;136(3):157-164 - PubMed
  35. Ophthalmology. 2005 Jan;112(1):10-9 - PubMed
  36. Invest Ophthalmol Vis Sci. 1985 Dec;26(12):1750-8 - PubMed
  37. Doc Ophthalmol. 2013 Dec;127(3):201-15 - PubMed
  38. Neurology. 2014 Jun 17;82(24):2165-72 - PubMed
  39. Eur J Neurol. 1999 Mar;6(2):151-62 - PubMed
  40. Transl Vis Sci Technol. 2017 May 22;6(3):5 - PubMed
  41. Eye (Lond). 2014 Oct;28(10):1206-11 - PubMed
  42. Clin Neurophysiol. 2006 May;117(5):1158-66 - PubMed
  43. J Glaucoma. 2014 Oct-Nov;23(8):494-500 - PubMed
  44. Am J Ophthalmol. 1997 Jan;123(1):103-7 - PubMed
  45. Doc Ophthalmol. 2013 Feb;126(1):1-7 - PubMed
  46. Brain. 1996 Jun;119 ( Pt 3):723-40 - PubMed
  47. Doc Ophthalmol. 2011 Dec;123(3):173-8 - PubMed
  48. Electroencephalogr Clin Neurophysiol. 1996 Sep;100(5):428-35 - PubMed

Publication Types

Grant support